大型蓝筹股多数下跌，汇丰控股收报138.219港元，较香港收市涨0.45%；腾讯控股收报619.286港元，较香港收市跌0.44%。 | 序号 | 名称 | 港股代码 | 最新价 | 涨跌额 | 涨跌幅 | ADRIETS | ADR换复价(HKD) | 较港股升跌 灰冷 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 腾讯控股 | ○ 00700 | 622.000 | +1.000 | 0.16% | TCEHY | 619.286 | -2.714 | | 2 | 阿里巴巴-W | 09988 | 173.300 | -0.200 | -0.12% | BABA | 170.013 | -3.287 | | 3 | 汇丰控股 | 00005 | 137.600 | +0.100 | 0.07% | HSBC | 138.219 | +0.619 | | 4 | 建设银行 | 00939 | 8.160 | +0.130 | 1.62% | CICHY | 8.086 | -0.074 | | 5 | 友邦保险 | 01299 ...

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their products, with significant business development (BD) transactions announced[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% increase year-on-year, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise, with a projected increase of 33-38% for NAND Flash products due to supply constraints[36] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - The goal is to achieve a 30% share of renewable energy in total power generation by 2030, indicating significant growth potential for the solar and wind energy sectors[46]

Market Performance - The market showed mixed performance from January 19 to January 23, with the Shanghai Composite Index rising by 0.84% and the Shenzhen Component Index increasing by 1.11%[5] - The average daily trading volume was 2.80 trillion yuan, a decrease compared to the previous week[5] Healthcare Sector - At the JPM 2026 conference, over 20 Chinese innovative pharmaceutical companies showcased their advancements, with significant business development (BD) transactions reported[16] - In 2025, the value of China's innovative drug patent licensing transactions reached approximately $135.7 billion, a 143% year-on-year increase, with 157 total transactions[20] Consumer Sector - The Qianwen APP integrated with Alibaba's ecosystem, achieving over 100 million monthly active users within two months of launch, marking its entry into the "billion-level club"[25] - This integration allows for a seamless process from search to decision-making and payment, establishing a comprehensive AI application ecosystem[26] Hard Technology Sector - The supply of storage and logic chips remains tight, leading to widespread price increases across the industry[32] - The price of enterprise SSDs continues to rise due to increased demand from AI servers, with NAND Flash supply expected to decrease by 41.7% in 2026[35] High-end Manufacturing - The State Grid announced a total fixed asset investment of 4 trillion yuan for the 14th Five-Year Plan period (2026-2030), a 40% increase from the previous period, averaging 800 billion yuan annually[42] - By 2030, renewable energy generation is expected to account for approximately 30% of total power generation, indicating significant growth potential in the solar and wind sectors[46]

Core Viewpoint - By 2025, China's innovative pharmaceuticals are expected to demonstrate significant global competitiveness, with record overseas transactions and many companies turning profitable [1][2]. Domestic Review - The global competitiveness of Chinese innovative drugs is highlighted, with a record-breaking overseas transaction total exceeding $135 billion in 2025, and upfront payments reaching $7 billion. The average deal size has increased from $600 million to $900 million [2]. - A comprehensive support system from policy, including review and approval processes to medical insurance payments, is being established, leading to a rapid increase in market share for innovative drugs, particularly in oncology and immunology, which now exceeds 32% [2]. - Companies like BeiGene and Innovent Biologics have already turned profitable, with others like CanSino Biologics and Zai Lab expected to follow suit in the next three years, indicating a positive cycle of capital influx, R&D iteration, and value realization [2]. Overseas Review - The S&P Biotechnology Index has risen over 50% from its bottom in the second half of 2025, driven by interest rate cuts that have shifted funds from tech stocks to biotech [3]. - Major pharmaceutical companies (MNCs) are actively pursuing mergers and acquisitions to supplement their pipelines, particularly in oncology and immunology, as they face a "patent cliff" with key drugs like Keytruda and Opdivo losing patent protection by 2027-2028 [3]. Assessment - Chinese companies are becoming significant partners for the top 20 MNCs, with Chinese transaction amounts accounting for 40% of the global innovative drug market. China is transitioning from a "fast-follower" to a "smart-innovator" in fields like PD-1 bispecific antibodies, ADCs, and small nucleic acids, leading in pipeline numbers and clinical progress [4]. - The speed and cost advantages of Chinese innovative drug companies are notable, with patient recruitment occurring at 2-5 times the speed of international counterparts and costs being half that of Western companies [4]. Key Tracks and Investment Opportunities - Bispecific antibodies are expected to surpass $120 billion in global sales, with Chinese companies leading the development of second-generation IO products [5]. - ADCs are seeing significant contributions from China, with over half of the global pipeline, and are expected to achieve proof of concept (POC) validation by 2026 [5]. - Combination therapies in oncology are showing synergistic effects, with key clinical data expected in 2026 [5]. - The market for iRAS inhibitors is projected to exceed $8 billion in the U.S., with critical breakthroughs anticipated in 2026 [5]. - Small nucleic acids are expanding into broader applications, with key products expected to commercialize and deliver critical data in 2026 [5]. - Protein degradation technologies are advancing rapidly, with numerous autoimmune disease targets expected to yield data in 2026 [5]. - The metabolic and cardiovascular fields are also poised for breakthroughs, with new targets addressing issues like muscle loss associated with GLP-1 therapies [5]. Main Lines and Recommended Focus - Recommended companies in the bispecific antibody space include CanSino Biologics, Innovent Biologics, and others [7]. - ADC-focused companies include I-Mab, Kelun-Biotech, and others [7]. - Small nucleic acid companies to watch include Ribobio, BIBO, and others [7]. - Strategic combinations to consider include CanSino Biologics, BeiGene, and others [8]. - Flexible combinations include BIBO, Eifang Biologics, and others [8]. - Stable combinations include Hengrui Medicine, China National Pharmaceutical Group, and others [8].

Market Overview - The Hang Seng Index (HSI) closed at 26,752.51, down by 13.01 points or 0.05% as of January 26, 16:00 Eastern Time [1] - The index reached a high of 26,826.45 and a low of 26,622.25 during the trading session, with a trading volume of 35.7947 million [1] - The 52-week high for the index is 27,275.90, while the 52-week low is 19,335.70, indicating a trading range of 0.76% [1] Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 132.695, up by 1.29% compared to the Hong Kong market close [2] - Tencent Holdings closed at HKD 600.708, reflecting a slight increase of 0.2% from the Hong Kong market close [2] - Alibaba Group (BABA) saw a decline of 1.96%, closing at HKD 165.200 [3] - Xiaomi Group (01810) decreased by 2.81%, closing at HKD 35.220 [3] - AIA Group (01299) remained unchanged at HKD 83.050 [3] Notable Stock Movements - New World Development (00016) experienced a significant increase of 3.93%, closing at HKD 119.000 [3] - Kuaishou Technology (01024) fell by 3.26%, closing at HKD 78.600 [3] - JD.com (09618) rose by 1.05%, closing at HKD 116.000 [3] - Ctrip Group (09961) increased by 1.40%, closing at HKD 492.200 [3]

张大伟 制图 ◎记者 何昕怡 受益于行业景气度日渐回暖、海外市场持续开拓、医药利好政策陆续落地，A股生物医药公司2025年在 韧性发展中不断交出创新的成绩单。 Wind数据显示，截至1月26日18时，已有超过90家A股生物医药公司发布2025年业绩预告，共有53家公 司预计实现盈利。从预告净利润增幅下限来看，有14家公司预计净利润倍增（剔除扭亏、减亏）。此 外，以岭药业、楚天科技等10家公司预计实现扭亏为盈，迪哲医药、盟科药业等14家公司同比实现减 亏。 其中，纳微科技核心业务中色谱填料和层析介质产品2025年销售收入预计实现约23%的增长，液相色谱 柱及样品前处理产品销售收入实现约32%的增长。公司持续加大国际市场拓展力度，预计实现国际业务 收入约8400万元，同比增长约79%。 国际化助力开拓增量市场 国际化业务是生物医药企业业绩增长的另一个助推器。 2025年初以来，受益于创新药行业发展、订单复苏明显，CXO公司表现强劲。作为CXO龙头，药明康 德预计：2025年实现营业收入454.56亿元，同比增长约15.84% ；实现归母净利润191.51亿元，同比增长 102.65%。 销售放量拉动业绩增长 在目 ...

【环球网财经综合报道】随着2025年基金四季报的密集披露，公募基金的持仓路径图全景式展现在投资者面前。数据 宝最新统计显示，截至去年四季度末，共有2977只股票现身基金重仓股名单。从机构控盘程度来看，基金调仓换股的 动向颇为明显，其中共有107只个股的基金持股比例超过10%，显示出机构资金对这些个股具有极高的话语权和控盘 力。 机构抱团现象在基金高比例持仓股中依然显著。一般而言，基金控盘比例高的个股往往伴随着多家基金扎堆持有。数 据显示，这107只个股中，有100家以上基金扎堆持有的多达42只，50至99家基金集体持有的有29只。值得注意的是， 宁德时代虽然持股比例为11.63%，但持有基金家数最多，高达2056家基金抱团持有。中际旭创、紫金矿业、新易盛的 持有基金家数也均超过1300家，分别达到1809家、1800家和1396家。 从板块分布来看，基金高比例持仓的个股呈现出明显的"硬科技"与"创新"特征。107只个股中，科创板有42只，创业板 有27只，沪深主板有31只，北交所有7只。行业分布上，电子、医药生物、电力设备三大行业成为机构最青睐的领 域，分别有28只、20只、11只个股上榜。这表明在当前的宏观 ...

李霁阳 方正证券医药分析师: 各位投资人下午好，我是方正证券医药组的分析师李季阳，然后我们今天的周周谈的会议 的话，是总结一下，据拼某个会议当中，中国创效公司的一些更新和进展。然后另外的话 就是大家对于近期整个整体创效的这个调整。然后我们也做一个市场的一个解读。首先的 话， JP Morgan 是在上周末结束，然后像百济百天恒，科伦博泰这些公司也是在主会场做 了这个 presentation 那我们可以看到其实公司的这个进展还是非常多的。就首先百济的 话，它的这个 BCL 2 是在中国已经获批上市了，而且年内的话，是有望在这个美国获得一 个加速的获批。 那 BCL2 其实对于百济来说，也相当于是它的第二个驱动增长的一个引擎，因为 BTK BK 我们可以看到近两年在美国市场的这个销售增速是非常快的。那我们预计的话，BCL2 上 市之后也会补全在一线 C CL 这个适应症当中的。这个拼图，然后也会助力它在未来两年 继续保持这个高速增长。因为其实投资人还是对于未来几年这个 BDK 的一个增速，因为 它毕竟体量提量到了一个比较大的一个这个体量了。就后续的增速其实大家还是有一些质 疑和担心，但是 BCL 2 上市之后， ...

2026年1月16日，陈影从旧金山飞回上海，飞机上坐满了中国创新药企的创始人、高管、投资者，大部分人看上去心情不错，他们刚参加完全球规模最大的 医疗健康盛会——摩根大通医疗健康大会（下称"JPM"）。 这是陈影第一次参加JPM。2025年10月，她所在的赛默罗生物收到了几家跨国药企的邀请，希望能在JPM期间洽谈合作。赛默罗生物有一款原始创新（first- in-class）药物已进入临床二期试验，并获得美国食品药品监督管理局（FDA）的孤儿药认定，这引起了跨国药企的兴趣。 陈影此行与五六家跨国公司进行了一对一会谈，奔波在会场、各大洽谈室之间，每天睡觉不超过5小时。许多参会者都有类似体验，赫吉亚生物创始人崔坤 元开玩笑说，参会最直接的收获是"比较累"。大家期望在四天的日程里尽可能捕捉最前沿的行业信息、与意向合作方深入沟通。 多位受访者对经济观察报表示，相比前几年，2026年JPM带来的正向预期更明显。尤其是对中国创新药企，几乎每家跨国公司都不掩饰对中国资产的兴趣。 经济观察报 记者 张英 他观察到，尽管FDA官员在JPM期间提及了中美创新药竞争，但并未强调保护主义政策，更多提及的是美国医院、FDA如何优化临床试 ...

Market Overview - The US stock market indices showed mixed performance on Friday, with the Hang Seng Index ADR closing at 26,719.08 points, down by 30.43 points or 0.11% compared to the Hong Kong close [1]. Major Blue-Chip Stocks - HSBC Holdings closed at HKD 130.896, up by 0.69% from the Hong Kong close [2]. - Tencent Holdings closed at HKD 598.184, up by 0.54% from the Hong Kong close [2]. Stock Performance Summary - Tencent Holdings (HKD 595.000) saw a decrease of HKD 2.500, or -0.42%, with its ADR price at HKD 598.184, reflecting an increase of HKD 3.184 or 0.54% [3]. - Alibaba Group (HKD 168.500) increased by HKD 3.700, or 2.25%, with its ADR price at HKD 168.834, up by HKD 0.334 or 0.20% [3]. - HSBC Holdings (HKD 130.000) rose by HKD 0.300, or 0.23%, with its ADR price at HKD 130.896, up by HKD 0.896 or 0.69% [3]. - Xiaomi Group (HKD 36.240) increased by HKD 1.000, or 2.84%, with its ADR price at HKD 36.287, up by HKD 0.047 or 0.13% [3]. - AIA Group (HKD 83.050) rose by HKD 0.550, or 0.67%, with its ADR price at HKD 83.077, up by HKD 0.027 or 0.03% [3]. - Meituan (HKD 97.550) increased by HKD 0.550, or 0.57%, with its ADR price at HKD 97.735, up by HKD 0.185 or 0.19% [3]. - Kuaishou (HKD 81.250) rose by HKD 2.150, or 2.72%, with its ADR price at HKD 82.648, up by HKD 1.398 or 1.72% [3]. - Ctrip Group (HKD 485.400) increased by HKD 3.800, or 0.79%, with its ADR price at HKD 490.273, up by HKD 4.873 or 1.00% [3].